The prognostic value of apoptotic marker (CD95) in adult acute leukemias

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  2017-01-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.11648/J.IJCOCR.20160101.11
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• International System for Human Cytogenetic Nomenclature

  2020cited by this paper
• Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling.

  2013cited by this paper
• Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.

  2008cited by this paper
• New Approaches and Therapeutics Targeting Apoptosis in Disease

  2005cited by this paper
• Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON‐SAKK co‐operative group studies

  2005cited by this paper
• Death receptors in chemotherapy and cancer

  2004cited by this paper
• Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia.

  2004cited by this paper
• Signaling pathways activated by daunorubicin.

  2001cited by this paper
• A Diverse Family of Proteins Containing Tumor Necrosis Factor Receptor-associated Factor Domains*

  2001cited by this paper
• CD95's deadly mission in the immune system

  2000cited by this paper
• Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?

  2000cited by this paper
• Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia

  2000cited by this paper
• Fas Antigen Expression on CD 34 ’ Human Marrow Cells Is Induced by Interferon y and Tumor Necrosis Factor ( Y and Potentiates Cytokine-Mediated Hematopoietic Suppression In Vitro

  2000cited by this paper
• Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

  2000cited by this paper
• CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia.

  1998cited by this paper
• Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells

  1997cited by this paper
• Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy.

  1997cited by this paper
• Fas-mediated apoptosis in cultured human eosinophils.

  1996cited by this paper
• Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy

  1996cited by this paper
• Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias.

  1995cited by this paper
• Mechanisms and genes of cellular suicide

  1995cited by this paper
• Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils.

  1994cited by this paper
• Human Fas ligand: gene structure, chromosomal location and species specificity.

  1994cited by this paper
• Induction of apoptosis in fibroblasts by c-myc protein.

  1992cited by this paper
• Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood.

  1992cited by this paper
• A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor

  1989cited by this paper

• The Results of MSC-428 NanomoleculesApplication in Neoadjuvant Therapy inPatients with Breast Cancer

  2019cites this paper